figitumumab + pegvisomant

**figitumumab + pegvisomant** is a combination of two distinct drugs: - **figitumumab** is a fully human monoclonal antibody targeting the insulin-like growth factor 1 receptor (IGF-1R), functioning as an antagonist. It has been investigated primarily in cancer (notably, various solid tumors, such as non-small cell lung cancer), intending to block IGF-1R-mediated signaling that contributes to tumor growth and survival. - **pegvisomant** is a genetically engineered, pegylated analog of human growth hormone that acts as a highly selective growth hormone receptor (GHR) antagonist. It is approved for the treatment of **acromegaly** and works by preventing growth hormone-mediated activation of its receptor, thereby reducing levels of insulin-like growth factor 1 (IGF-1)[1][2][3][4][5]. There is no known brand or clinical combination product marketed as "figitumumab + pegvisomant"; thus, this is considered a research or hypothetical combination.